Compare Merck & Co., Inc. (MRK) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Royal Caribbean Cruises Ltd — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Royal Caribbean Cruises Ltd trades at $282.26 (market cap $75.26B). The key difference: Merck & Co., Inc. is far larger — about 4.7× Royal Caribbean Cruises Ltd's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| MRK | RCL | |
|---|---|---|
Market Cap | $351.28B | $75.26B |
Volume | 7,969,665 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $348.03 |
52-Week Low | $82.49 | $230.30 |
Typical Hold Time | 98 Days | 85 Days |
Enterprise Value | $398.04B | $97.91B |
Dividend Yield | 2.39% | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Royal Caribbean (RCL) trades at $281.39, down 0.35% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with 2025 revenue of $17.93B and net income of $4.27B, representing a 23.54% margin. Recent Q2 2026 earnings beat expectations at $4.21 EPS versus $3.98 expected, while the company expands into resorts through a $3B Sandals stake acquisition announced September 2026.
RCL presents a compelling growth story with improving profitability and strategic expansion, though elevated valuation multiples and high debt levels warrant caution. Analyst consensus remains bullish with a $346.67 price target representing 23% upside potential, but investors should monitor execution risks from the Sandals integration and sensitivity to fuel costs projected at $1.34B for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
